What Changed

Ascendis Pharma A/S, the Copenhagen-based company listed on Nasdaq under ASND, announced on September 14, 2026 that it has authorized a share repurchase program. The company describes itself as a global biopharmaceutical company focused on applying its innovative TransCon technology platform, and it maintains additional facilities in Europe and the United States.

Highlights

  • Ascendis Pharma A/S is headquartered in Copenhagen, Denmark, and trades on Nasdaq under the ticker ASND.
  • The company describes itself as a global biopharmaceutical company focused on applying its innovative TransCon technology platform.
  • The repurchase program carries no mandatory repurchase requirement and may be modified, suspended or terminated at any time without notice.
  • Repurchases may be carried out through open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, or purchases through 10b5-1 trading plans.

Who Is Affected

If you hold shares of ASND, the buyback itself does not obligate the company to purchase any set number of shares, because the program carries no mandatory repurchase requirement. The timing and volume of any purchases will be determined based on market conditions, share price and other factors, and the company has said the program may be modified, suspended or terminated at any time without notice.

How Repurchases May Be Carried Out

Ascendis Pharma has said it may execute purchases through open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or any combination of these methods.

What To Watch Next

Investors following the filings history can note that the company's most recent annual report was filed on February 11, 2026. Those with questions can reach the investor relations line at +1 (650) 519-7494 or the media contact at +1 (650) 709-8875.